BioTime Acquires Asterias Biotherapeutics with Two of its Clinical Stage Cell Therapy Candidates
Shots:
- Asterias to receive 0.71 share- for each of its share in BioTime making it an ownership of 16.2%. Biotime to get hold of all stock of Asterias along with two clinical stage candidates i.e. OPC1 & VAC2
- The focus of the acquisition is to develop & commercialize novel therapies in fields of Immuno-oncology & Neurology
- OPC1 is a therapy utilizing oligodendrocyte progenitor cells (OPCs)- is currently evaluated in P-II for the treatment of Severe Spinal Cord Injury. VAC2 is an immunotherapy candidate- currently evaluated in P-I for the treatment of NSCLC in collaboration with Cancer Research UK
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
